Federated Hermes Inc. Invests $1.76 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Federated Hermes Inc. purchased a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 531,221 shares of the biotechnology company’s stock, valued at approximately $1,758,000. Federated Hermes Inc. owned about 0.89% of Aldeyra Therapeutics at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ALDX. Price T Rowe Associates Inc. MD grew its holdings in Aldeyra Therapeutics by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 3,446 shares during the period. Laidlaw Wealth Management LLC grew its stake in shares of Aldeyra Therapeutics by 32.6% during the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 4,150 shares during the period. BNP Paribas Financial Markets increased its holdings in Aldeyra Therapeutics by 23.4% in the first quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 4,797 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Aldeyra Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 6,944 shares during the last quarter. Finally, Woodstock Corp lifted its stake in Aldeyra Therapeutics by 5.9% in the second quarter. Woodstock Corp now owns 180,806 shares of the biotechnology company’s stock valued at $598,000 after buying an additional 10,091 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Stock Down 2.5 %

Shares of ALDX stock opened at $5.89 on Friday. Aldeyra Therapeutics, Inc has a 12-month low of $1.42 and a 12-month high of $6.74. The firm has a fifty day moving average of $4.94 and a 200-day moving average of $4.13. The firm has a market capitalization of $349.95 million, a price-to-earnings ratio of -11.55 and a beta of 1.45.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.